• Home
  • About
  • Editorial Board
  • Submissions
EFFECT OF INTRAVENOUS IMMUNOGLOBULIN ON INFECTIONS IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING DARATUMUMAB
April 12th, 2021
Anti-CD38 monoclonal antibodies have led to improved response rates, progression-free and overall survival in randomized clinical trials (RCTs) of multiple myeloma (MM) patients. ...  Read More
IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB...
April 12th, 2021
Long-term PI-based treatment is associated with improved outcomes in MM. Nonetheless, prolonged therapy with parenteral PIs (e.g. bortezomib) can be challenging in the real world, with median duration...  Read More
METRONOMIC THERAPY FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
March 3rd, 2021
Lorem ipsum dolor sit amet, consectetur adipiscing elit. In commodo vehicula velit, a vestibulum mi maximus in. Nulla at lectus tincidunt, mollis lectus vestibulum, congue metus. Morbi feugiat dolor s...  Read More

Recent

EFFECT OF INTRAVENOUS IMMUNOGLOBULIN ON INFECTIONS IN MULTIPLE MYELOMA (MM) PATIENTS RECEIVING DARATUMUMAB
April 12th, 2021
IN-CLASS TRANSITION (ICT) FROM PARENTERAL BORTEZOMIB...
April 12th, 2021
METRONOMIC THERAPY FOR RELAPSED REFRACTORY MULTIPLE MYELOMA
March 3rd, 2021

Categories

Basal Cell Cancer
Breast Cancer
Colon Cancer
Gastrointestinal Cancer
Melanoma Skin Cancers
Multiple Myeloma
Oncology
Prostate Cancer

Tags

no tags
© Copyright Robinhood Health - 2021 Journal HEM-ONC
750 Boston Neck Road
Suite 11, Narragansett, RI 02882
PHONE: (877) 745-2445
FAX: (855) 891-8303
powered by  SnapPages